medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Número 1

<< Anterior Siguiente >>

Rev Mex Urol 2025; 85 (1)


Epidemiología del cáncer de próstata: análisis comparativo de los principales cánceres urológicos

Guzmán EJ, Guzmán SHP, Delgado EI

Idioma: Español
Referencias bibliográficas: 23
Paginas: 1-10
Archivo PDF: 157.87 Kb.


RESUMEN

El cáncer se presenta como una de las principales causas de mortalidad a nivel global y su incidencia muestra una tendencia ascendente, atribuible al envejecimiento poblacional, la implementación de nuevas herramientas diagnósticas y la disponibilidad de terapias innovadoras. En el hombre, el cáncer de próstata destaca como una de las neoplasias con mayor incidencia y prevalencia, asociado además a una elevada tasa de mortalidad excluyendo el cáncer de piel. El conocimiento detallado de la incidencia, la mortalidad y, en particular, la carga de enfermedad de esta neoplasia reviste suma relevancia, ya que permite la formulación e implementación de medidas y estrategias en las políticas de salud, con el objetivo de mitigar el impacto negativo tanto en la salud pública como en la economía de los países. A nivel global en el año 2021, se registraron 432 463 defunciones por cáncer de próstata, mientras que en México la cifra ascendió a 8860. En México y el mundo, el cáncer de próstata es una neolplasia muy prevalente y representa una alta carga de enfermedad. La intervención oportuna es necesaria para mitigar su impacto.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bray F, Laversanne M, Weiderpass E,Soerjomataram I. The ever-increasingimportance of cancer as a leading causeof premature death worldwide. Cancer. 2021;127(16): 3029–3030. https://doi.org/10.1002/cncr.33587.

  2. Ferlay J, Ervik M, Lam F, Colombet M, MeryL, Piñeros M, et al. Global cancer observatory:cancer today. Lyon: International agency forresearch on cancer. 2020;20182020.

  3. Bray F, Soerjomataram I. The ChangingGlobal Burden of Cancer: Transitions inHuman Development and Implications forCancer Prevention and Control. In: GelbandH, Jha P, Sankaranarayanan R, Horton S (eds.)Cancer: Disease Control Priorities, ThirdEdition (Volume 3). Washington (DC): TheInternational Bank for Reconstruction andDevelopment / The World Bank; 2015. http://www.ncbi.nlm.nih.gov/books/NBK343643/

  4. Tian YQ, Yang JC, Hu JJ, Ding R, Ye DW, ShangJW. Trends and risk factors of global incidence,mortality, and disability of genitourinarycancers from 1990 to 2019: Systematic analysisfor the Global Burden of Disease Study 2019.Frontiers in Public Health. 2023;11: 1119374.https://doi.org/10.3389/fpubh.2023.1119374.

  5. Bray F, Laversanne M, Sung H, Ferlay J,Siegel RL, Soerjomataram I, et al. Globalcancer statistics 2022: GLOBOCAN estimatesof incidence and mortality worldwide for 36cancers in 185 countries. CA: a cancer journalfor clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.

  6. Zi H, He SH, Leng XY, Xu XF, Huang Q, WengH, et al. Global, regional, and national burden ofkidney, bladder, and prostate cancers and theirattributable risk factors, 1990-2019. MilitaryMedical Research. 2021;8(1): 60. https://doi.org/10.1186/s40779-021-00354-z.

  7. Su X, Tao Y, Chen F, Han X, Xue L. Trends in theglobal, regional, and national burden of bladdercancer from 1990 to 2021: an observationalstudy from the global burden of disease study2021. Scientific Reports. 2025;15(1): 7655.https://doi.org/10.1038/s41598-025-92033-5.

  8. Cirillo L, Innocenti S, Becherucci F. Globalepidemiology of kidney cancer. Nephrology,Dialysis, Transplantation: Official Publicationof the European Dialysis and TransplantAssociation - European Renal Association.2024;39(6): 920–928. https://doi.org/10.1093/ndt/gfae036.

  9. Siegel RL, Miller KD, Jemal A. Cancer statistics,2020. CA: a cancer journal for clinicians.2020;70(1): 7–30. https://doi.org/10.3322/caac.21590.

  10. World Health Organization. The GlobalInitiative for Childhood Cancer. World HealthOrganization. 2023. https://www.who.int/initiatives/the-global-initiative-for-childhoodcancer

  11. World Health Organization. SDG Target3.4 | Noncommunicable diseases and mentalhealth: By 2030, reduce by one third prematuremortality from non-communicable diseasesthrough prevention and treatment and promotemental health and well-being. The Global HealthObservatory.2024 https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.4-noncommunicable-diseases-and-mental-health

  12. dos-Santos-Silva I, Gupta S, Orem J, ShulmanLN. Global disparities in access to cancer care.Communications Medicine. 2022;2: 31. https://doi.org/10.1038/s43856-022-00097-5.

  13. Mattiuzzi C, Lippi G. Current CancerEpidemiology. Journal of Epidemiology andGlobal Health. 2019;9(4): 217–222. https://doi.org/10.2991/jegh.k.191008.001.

  14. US Preventive Services Task Force,Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screeningfor Prostate Cancer: US Preventive ServicesTask Force Recommendation Statement.JAMA. 2018;319(18): 1901–1913. https://doi.org/10.1001/jama.2018.3710.

  15. American cancer Society (apellido). KeyStatistics for Prostate Cancer. American cancerSociety. 2025.

  16. International Agency for Research on Cancer.Cancer Today. 2025. https://gco.iarc.who.int/today/

  17. James ND, Tannock I, N’Dow J, Feng F, GillessenS, Ali SA, et al. The Lancet Commission onprostate cancer: planning for the surge in cases.Lancet (London, England). 2024;403(10437):1683–1722. https://doi.org/10.1016/S0140-6736(24)00651-2.

  18. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC,Brawley O, et al. Prostate Cancer Incidenceand PSA Testing Patterns in Relation toUSPSTF Screening Recommendations. JAMA.2015;314(19): 2054–2061. https://doi.org/10.1001/jama.2015.14905.

  19. Moyer VA, U.S. Preventive Services Task Force.Screening for prostate cancer: U.S. PreventiveServices Task Force recommendation statement.Annals of Internal Medicine. 2012;157(2): 120–134. https://doi.org/10.7326/0003-4819-157-2-201207170-00459.

  20. Borregales LD, DeMeo G, Gu X, Cheng E,Dudley V, Schaeffer EM, et al. Grade Migrationof Prostate Cancer in the United States Duringthe Last Decade. Journal of the National CancerInstitute. 2022;114(7): 1012–1019. https://doi.org/10.1093/jnci/djac066.

  21. Bergengren O, Pekala KR, Matsoukas K,Fainberg J, Mungovan SF, Bratt O, et al. 2022Update on Prostate Cancer Epidemiology andRisk Factors—A Systematic Review. Europeanurology. 2023;84(2): 191–206. https://doi.org/10.1016/j.eururo.2023.04.021.

  22. Zlotta AR, Egawa S, Pushkar D, Govorov A,Kimura T, Kido M, et al. Prevalence of prostatecancer on autopsy: cross-sectional study onunscreened Caucasian and Asian men. Journalof the National Cancer Institute. 2013;105(14):1050–1058. https://doi.org/10.1093/jnci/djt151.

  23. Johns LE, Houlston RS. A systematic review andmeta-analysis of familial prostate cancer risk.BJU international. 2003;91(9): 789–794. https://doi.org/10.1046/j.1464-410x.2003.04232.x.




2020     |     www.medigraphic.com